ArticleScientific reports2025
HPCAL1 as a novel prognostic biomarker in acute myeloid leukemia and its correlation with immune infiltrates.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute myeloid leukemia (AML), a heterogeneous malignancy with complex molecular mechanisms, urgently requires improved prognostic biomarkers and therapeutic targets. This study investigated Hippocalcin-like 1（HPCAL1）, a calcium-binding protein with dual functionality dependent on cancer type, as a potential prognostic marker and investigated its interaction with the tumor immune microenvironment in AML. Through analyses of multiple independent cohorts (GSE13159, GSE34184, GSE24395 and institutional data), we revealed that significant HPCAL1 overexpression in AML samples was correlated with poor survival outcomes. ESTIMATE analysis revealed increased immune activity in the HPCAL1-high group, which was supported by differential expression profiling, which identified 617 genes enriched in inflammatory/immune pathways. Coexpression network and protein interaction analyses further implicated HPCAL1 in immune regulation, particularly through NOD-like receptor signaling, as confirmed by GSEA/GSVA. Single-cell RNA sequencing analysis of the GSE130756 dataset revealed monocyte-specific HPCAL1 expression with altered cellular communication patterns in AML, whereas deconvolution analysis revealed that increased monocyte proportions in HPCAL1-high samples were associated with adverse prognoses. Our findings establish HPCAL1 as a novel prognostic indicator in AML, potentially by mediating its effects through immune microenvironment modulation and monocyte population dynamics. These results provide a foundation for future mechanistic studies exploring the role of HPCAL1 in AML pathogenesis and its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.